Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TYK Medicines Stages $74 Million Hong Kong IPO

publication date: Aug 16, 2024

TYK Medicines is staging a Hong Kong IPO that will raise US$74 million to support its portfolio of small molecule cancer drugs. TYK is developing 11 drug candidates (including its core product TY-9591), six clinical-stage products and four preclinical or early-stage clinical development products. One year ago, TY-9591 started a pivotal Phase II trial as a first-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases. TY-9591 was designed to improve the efficacy of AstraZeneca’s Tagrisso (osimertinib), and it will be compared to osimertinib in the trial. TYK Medicines is headquartered in Huzhou, Zhejiang province China. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here